Trademark Overview
On Thursday, April 16, 2026, a trademark application was filed for ELISIGENETICS with the United States Patent and Trademark Office. The USPTO has given the ELISIGENETICS trademark a serial number of 99769457. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Thursday, April 16, 2026. This trademark is owned by ELISIGEN INC.. The ELISIGENETICS trademark is filed in the Pharmaceutical Products, Advertising, Business and Retail Services, and Computer & Software Services & Scientific Services categories with the following description:
Wholesale distributorships featuring pharmaceutical
preparations for the treatment of sensory organ disorders; Wholesale distributorships featuring pharmaceutical
preparations for the treatment of peripheral nervous system
disorders; Wholesale distributorships featuring pharmaceutical
preparations for the treatment of central nervous system
disorders; Wholesale distributorships featuring analgesics; Wholesale distributorships featuring immunomodulators; Wholesale distributorships featuring vaccines; Wholesale distributorships featuring chemical preparations for
use in the manufacture of pharmaceuticals; Wholesale distributorships featuring biological preparations for
medical and veterinary purposes; Wholesale distributorships featuring pharmaceutical
preparations for the treatment of allergies; Wholesale distributorships featuring cosmetics
Scientific research in the field of pharmacogenetics; Research and development in the field of gene-based
pharmaceuticals; Research and development services in the field of gene expression systems; Gene therapy research; Research in the field of gene editing technology; Scientific research in the field of genetics; Research and development in the field of therapeutic peptides; Pharmaceutical research and development; Research and development services in the field of cosmetics; Food research
Nucleic acid sequences for medical and veterinary purposes; Synthetic peptides for pharmaceutical purposes; Cells for medical purposes; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of sensory organ disorders; Pharmaceutical preparations for the treatment of peripheral nervous system disorders; Pharmaceutical preparations for the treatment of tinnitus; Pharmaceutical preparations for the treatment of central nervous system disorders; Pain relief medication; Analgesics; Vaccines; Tranquilizers; Diagnostic preparations for medical purposes; Drug delivery agents in the form of coatings for tablets that facilitate the delivery of pharmaceutical preparations; Pharmaceutical preparations for the treatment of allergies